Your browser doesn't support javascript.
loading
DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets.
Lozinski, Mathew; Bowden, Nikola A; Graves, Moira C; Fay, Michael; Tooney, Paul A.
Afiliación
  • Lozinski M; School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Newcastle, NSW, Australia.
  • Bowden NA; Centre for Drug Repurposing and Medicines Research, University of Newcastle, Newcastle, NSW, Australia.
  • Graves MC; Hunter Medical Research Institute, Newcastle, NSW, Australia.
  • Fay M; Centre for Drug Repurposing and Medicines Research, University of Newcastle, Newcastle, NSW, Australia.
  • Tooney PA; Hunter Medical Research Institute, Newcastle, NSW, Australia.
Cell Oncol (Dordr) ; 44(5): 961-981, 2021 Oct.
Article en En | MEDLINE | ID: mdl-34057732
ABSTRACT

BACKGROUND:

The aggressive, invasive and treatment resistant nature of glioblastoma makes it one of the most lethal cancers in humans. Total surgical resection is difficult, and a combination of radiation and chemotherapy is used to treat the remaining invasive cells beyond the tumour border by inducing DNA damage and activating cell death pathways in glioblastoma cells. Unfortunately, recurrence is common and a major hurdle in treatment, often met with a more aggressive and treatment resistant tumour. A mechanism of resistance is the response of DNA repair pathways upon treatment-induced DNA damage, which enact cell-cycle arrest and repair of DNA damage that would otherwise cause cell death in tumour cells.

CONCLUSIONS:

In this review, we discuss the significance of DNA repair mechanisms in tumour formation, aggression and treatment resistance. We identify an underlying trend in the literature, wherein alterations in DNA repair pathways facilitate glioma progression, while established high-grade gliomas benefit from constitutively active DNA repair pathways in the repair of treatment-induced DNA damage. We also consider the clinical feasibility of inhibiting DNA repair in glioblastoma and current strategies of using DNA repair inhibitors as agents in combination with chemotherapy, radiation or immunotherapy. Finally, the importance of blood-brain barrier penetrance when designing novel small-molecule inhibitors is discussed.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Daño del ADN / Neoplasias Encefálicas / Glioblastoma / Resistencia a Antineoplásicos / Reparación del ADN Límite: Humans Idioma: En Revista: Cell Oncol (Dordr) Año: 2021 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Daño del ADN / Neoplasias Encefálicas / Glioblastoma / Resistencia a Antineoplásicos / Reparación del ADN Límite: Humans Idioma: En Revista: Cell Oncol (Dordr) Año: 2021 Tipo del documento: Article País de afiliación: Australia